Mexico Biobanking Market Size And Share Outlook: Forecast Trends And Growth Analysis Report (2025-2034)

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on biobanking equipment, automated storage, blood sample processing, AI-enabled analytics and precision medicine. Genomic initiatives and international partnerships create openings for pharma, biotech and research providers.

Dublin, Sept. 11, 2026 (GLOBE NEWSWIRE) -- "Mexico Biobanking Market Size and Share Outlook: Forecast Trends and Growth Analysis Report (2025-2034)" has been added to ResearchAndMarkets.com's offering.

Mexico Biobanking Market to Reach USD 1.58 Billion by 2034 as Genomic Research and AI Collaborations Expand

The Mexico biobanking market was valued at USD 1.10 billion in 2024 and is projected to reach USD 1.58 billion by 2034, expanding at a compound annual growth rate of 3.70% from 2025 to 2034. Market growth is being supported by national genomic initiatives, investment in advanced laboratory infrastructure, international research partnerships, and the increasing integration of artificial intelligence into precision medicine programs.

Mexico is strengthening its position within the regional life sciences sector as public agencies, universities, healthcare institutions, and private companies expand biological sample collection, storage, processing, and analysis capabilities. Growing demand for high-quality biospecimens is also supporting clinical research, drug development, molecular diagnostics, regenerative medicine, and population health studies.

Key Mexico Biobanking Market Highlights

• The market was valued at USD 1.10 billion in 2024.
• Revenue is forecast to reach USD 1.58 billion by 2034.
• The market is expected to register a CAGR of 3.70% between 2025 and 2034.
• Equipment is anticipated to lead the market by type during the forecast period.
• Blood products accounted for approximately 30% of the market by sample type during the historical period.
• Pharmaceutical and biotechnology companies are expected to remain prominent end users of biobanking products and services.

National Genomic Programs Support Market Expansion

Large-scale genetic research initiatives are creating significant opportunities in the Mexico biobanking market. The Mexican Biobank Project has generated genomic data from more than 6,000 individuals across all 32 Mexican states, contributing to the development of a more representative national genetic reference. The resulting data can support disease-risk analysis, treatment research, public health planning, and precision medicine strategies tailored to Mexico's diverse population.

Broader representation in genomic research is expected to improve the relevance and reliability of clinical studies. Increased awareness of biobanking and genomic science may also encourage public participation, enabling research institutions to develop larger and more diverse sample collections while strengthening Mexico's biomedical research ecosystem.

Artificial Intelligence Collaborations Accelerate Precision Medicine

The integration of artificial intelligence with large biobank datasets is emerging as an important Mexico biobanking market trend. In March 2025, universities in the United States and Mexico announced a collaboration combining AI capabilities with Latin America's largest biobank to investigate health disparities affecting Latino populations.

AI-supported analysis can increase the speed and scale at which genomic, clinical, and population data are evaluated. These collaborations are expected to advance biomarker discovery, disease prediction, treatment selection, and the development of precision healthcare programs. They may also attract additional institutional funding and technology investment to Mexico's life sciences industry.

International Partnerships Strengthen Research Capabilities

Cross-border academic and scientific partnerships are expanding Mexico's biobanking infrastructure and research capacity. In November 2024, the Instituto Politecnico Nacional and the University of Oxford partnered to establish a national biobank focused on colon cancer research. The initiative is designed to advance research into the genetic, cellular, and molecular characteristics of colon cancer within the Mexican population.

Access to international expertise, advanced research platforms, and shared datasets is expected to support improvements in disease diagnosis and personalized treatment development. Such initiatives also reinforce Mexico's potential to become a strategic center for biobanking, clinical research, and genomics in Latin America.

Blood Products Maintain a Strong Market Position

Blood products represent a leading sample category because of their extensive use in diagnostics, clinical research, transfusion medicine, therapeutic development, and molecular testing. Demand is being reinforced by the rising prevalence of chronic diseases, the expansion of personalized medicine, and improvements in healthcare and laboratory infrastructure.

Advances in sample processing, cold-chain logistics, automated storage, and quality-control systems are further improving the efficiency and integrity of blood-based collections. Human tissues, cell lines, nucleic acids, human waste products, and other biospecimens also contribute to the market's growth and diversification.

Competitive Landscape

Leading companies serving the Mexico biobanking market include Thermo Fisher Scientific Inc., PHC Holdings Corporation, Qiagen N.V., and Tecan Group Ltd. Other prominent participants include Becton, Dickinson and Company, Merck KGaA, Avantor Inc., Cryoport Inc., Azenta Inc., and Greiner AG.

These companies compete across laboratory instruments, temperature-controlled storage, molecular testing, automation, sample transport, consumables, and biobanking software. Strategic priorities include research and development, laboratory automation, AI integration, sustainable cold-storage technologies, regulatory compliance, distribution expansion, and institutional partnerships.

Mexico Biobanking Market Segmentation

The market is analyzed by type across equipment, consumables, services, and software. Equipment categories include storage, sample analysis, sample processing, and sample transport systems, while services include storage, processing, transportation, and supply support.

By storage type, the market comprises manual and automated storage. Sample categories include blood products, human tissues, cell lines, nucleic acids, human waste products, and other materials. Ownership categories cover universities, national and regional agencies, nonprofit organizations, and private organizations.

Major applications include regenerative medicine, life science research, and clinical research. Key end users include pharmaceutical and biotechnology companies, hospitals and healthcare providers, academic and research institutions, and other organizations requiring secure biological sample management.

Continued investment in genomic programs, automated laboratory technology, AI-enabled research, and international scientific partnerships is expected to sustain the Mexico biobanking market's long-term development through 2034.

Key Attributes:

Report Attribute	Details
No. of Pages	200
Forecast Period	2025 - 2034
Estimated Market Value (USD) in 2025	$1.1 Billion
Forecasted Market Value (USD) by 2034	$1.58 Billion
Compound Annual Growth Rate	3.7%
Regions Covered	Mexico

Key Topics Covered:
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Biobanking Market Overview
3.1 Latin America Biobanking Market
3.1.1 Latin America Biobanking Market Historical Value (2018-2024)
3.1.2 Latin America Biobanking Market Forecast Value (2025-2034)
3.2 Mexico Biobanking Market
3.2.1 Mexico Biobanking Market Historical Value (2018-2024)
3.2.2 Mexico Biobanking Market Forecast Value (2025-2034)
4 Mexico Biobanking Market Landscape*
4.1 Mexico Biobanking Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Mexico Biobanking Market: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Storage Type
4.2.3 Analysis by Ownership
5 Mexico Biobanking Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 PESTEL Analysis
5.3.1 Political
5.3.2 Economic
5.3.3 Social
5.3.4 Technological
5.3.5 Legal
5.3.6 Environment
5.4 Porter's Five Forces Model
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Buyers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitutes
5.4.5 Degree of Rivalry
5.5 Key Demand Indicators
5.6 Key Price Indicators
5.7 Industry Events, Initiatives, and Trends
5.8 Value Chain Analysis
6 Mexico Biobanking Market Segmentation (2018-2034)
6.1 Mexico Biobanking Market (2018-2034) by Type
6.1.1 Equipment
6.1.1.1 Storage Equipment
6.1.1.2 Sample Analysis Equipment
6.1.1.3 Sample Processing Equipment
6.1.1.4 Sample Transport Equipment
6.1.2 Consumables
6.1.2.1 Storage Consumables
6.1.2.2 Analysis Consumables
6.1.2.3 Processing Consumables
6.1.2.4 Collection Consumables
6.1.3 Services
6.1.3.1 Storage Services
6.1.3.2 Processing Services
6.1.3.3 Transport Services
6.1.3.4 Supply Services
6.1.4 Software
6.2 Mexico Biobanking Market (2018-2034) by Storage Type
6.2.1 Manual Storage
6.2.2 Automated Storage
6.3 Mexico Biobanking Market (2018-2034) by Sample Type
6.3.1 Blood Products
6.3.2 Human Tissues
6.3.3 Cell Lines
6.3.4 Nucleic Acid
6.3.5 Human Waste Products
6.3.6 Others
6.4 Mexico Biobanking Market (2018-2034) by Ownership
6.4.1 Universities
6.4.2 National/Regional Agencies
6.4.3 Non-Profit Organizations
6.4.4 Private Organizations
6.5 Mexico Biobanking Market (2018-2034) by Application
6.5.1 Regenerative Medicine
6.5.2 Life Science Research
6.5.3 Clinical Research
6.6 Mexico Biobanking Market (2018-2034) by End User
6.6.1 Pharmaceutical and Biotechnological Companies
6.6.2 Hospital and Healthcare Providers
6.6.3 Academic and Research Institutes
6.6.4 Other End Users
7 Regulatory Framework
8 Funding and Investment Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Strategic Initiatives
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Initiatives
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Supplier Landscape
10.1 Market Share Analysis
10.2 Thermo Fisher Scientific Inc.
10.2.1 Financial Analysis
10.2.2 Product/Service Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Company News and Developments
10.2.5 Certifications
10.3 PHC Holdings Corporation
10.3.1 Financial Analysis
10.3.2 Product/Service Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Company News and Developments
10.3.5 Certifications
10.4 Qiagen N.V.
10.4.1 Financial Analysis
10.4.2 Product/Service Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Company News and Developments
10.4.5 Certifications
10.5 Tecan Group Ltd.
10.5.1 Financial Analysis
10.5.2 Product/Service Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Company News and Developments
10.5.5 Certifications
10.6 Becton, Dickinson and Company (BD)
10.6.1 Financial Analysis
10.6.2 Product/Service Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Company News and Developments
10.6.5 Certifications
10.7 Merck KGaA
10.7.1 Financial Analysis
10.7.2 Product/Service Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Company News and Developments
10.7.5 Certifications
10.8 Avantor, Inc.
10.8.1 Financial Analysis
10.8.2 Product/Service Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Company News and Developments
10.8.5 Certifications
10.9 Cryoport Inc.
10.9.1 Financial Analysis
10.9.2 Product/Service Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Company News and Developments
10.9.5 Certifications
10.10 Azenta Inc.
10.10.1 Financial Analysis
10.10.2 Product/Service Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Company News and Developments
10.10.5 Certifications
10.11 Greiner AG
10.11.1 Financial Analysis
10.11.2 Product/Service Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Company News and Developments
10.11.5 Certifications
11 Mexico Biobanking Market - Distribution Model (Additional Insight)
11.1 Overview
11.2 Potential Distributors
11.3 Key Parameters for Distribution Partner Assessment
12 Key Opinion Leaders (KOL) Insights (Additional Insight)
Companies Featured

• Thermo Fisher Scientific Inc.
• PHC Holdings Corporation
• Qiagen N.V.
• Tecan Group Ltd.

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11092026004107003653ID1111651149